Payment overview · 2025
General Payments
$1,124.60
28 reported records · 13 companies
Healthcare provider profile · identity verified
Patrick David Morton, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · AVENTURA, FL · NPI 1578598702
Verified facts
What the public records show
CMS Open Payments records show Patrick David Morton, D.O. received $1,124.60 in general payments during 2025 across 28 reported records.
Novo Nordisk Inc accounted for 37.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Paxlovid, Rybelsus.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 212 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $423.15 | 37.6% | 6 | 2025 |
| Cleerly, Inc. | Unresolved — no canonical attribution shown | $166.40 | 14.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $126.69 | 11.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $99.27 | 8.8% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $69.00 | 6.1% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $41.86 | 3.7% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $37.05 | 3.3% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $36.30 | 3.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.62 | 2.7% | 2 | 2025 |
| InSightec,Inc | Unresolved — no canonical attribution shown | $29.83 | 2.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.30 | 2.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.71 | 1.9% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $20.42 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,124.60 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $267.92 | 3 | 2025 |
Source payment records
|
|||||
| Cleerly Ischemia Normalized: cleerly ischemia |
Device | Cleerly, Inc. | $166.40 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Labs Normalized: cleerly labs |
Device | Cleerly, Inc. | $166.40 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $155.23 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $126.69 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $99.27 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $78.27 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $50.18 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $41.86 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $37.05 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $36.30 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.62 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.62 | 2 | 2025 |
Source payment records
|
|||||
| Exablate Normalized: exablate |
Device | InSightec,Inc | $29.83 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $27.97 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $22.30 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.26 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $22.21 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $18.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 212 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 80 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 35 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 15 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
75 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
80 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
35 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
212 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 403 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 389 | 85 |
| Metformin Hcl | Metformin Hcl | 372 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 362 | 93 |
| Levothyroxine Sodium | Levothyroxine Sodium | 308 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 276 | 70 |
| Gabapentin | Gabapentin | 253 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 239 | 46 |
| Lactulose | Lactulose | 225 | 24 |
| Losartan Potassium | Losartan Potassium | 218 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 217 | 39 |
| Eliquis | Apixaban | 212 | 29 |
| Omeprazole | Omeprazole | 198 | 39 |
| Simvastatin | Simvastatin | 183 | 21 |
| Lisinopril | Lisinopril | 162 | 35 |
| Montelukast Sodium | Montelukast Sodium | 141 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 135 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 130 | 25 |
| Potassium Chloride | Potassium Chloride | 124 | 24 |
| Vascepa | Icosapent Ethyl | 113 | 11 |
| Gemtesa | Vibegron | 106 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 94 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 93 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 93 | 13 |
| Meloxicam | Meloxicam | 90 | 14 |
| Carvedilol | Carvedilol | 89 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 35 |
| Azithromycin | Azithromycin | 82 | 59 |
| Mounjaro | Tirzepatide | 80 | 11 |
| Jardiance | Empagliflozin | 75 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 74 | 42 |
| Famotidine | Famotidine | 73 | 23 |
| Furosemide | Furosemide | 73 | 19 |
| Xarelto | Rivaroxaban | 73 | 11 |
| Bumetanide | Bumetanide | 72 | 24 |
| Alprazolam | Alprazolam | 71 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | 18 |
| Levetiracetam | Levetiracetam | 69 | 12 |
| Prednisone | Prednisone | 69 | 38 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 67 | 31 |
| Linzess | Linaclotide | 64 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 63 | 25 |
| Propranolol Hcl | Propranolol Hcl | 63 | 12 |
| Donepezil Hcl | Donepezil Hcl | 61 | suppressed |
| Finasteride | Finasteride | 58 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | 15 |
| Metformin Hcl Er | Metformin Hcl | 52 | suppressed |
| Mirtazapine | Mirtazapine | 52 | 11 |
| Warfarin Sodium | Warfarin Sodium | 52 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 46 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 51 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 51 | 18 |
| Memantine Hcl | Memantine Hcl | 51 | suppressed |
| Ketoconazole | Ketoconazole | 50 | 21 |
| Latanoprost | Latanoprost | 49 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 49 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 46 | suppressed |
| Januvia | Sitagliptin Phosphate | 45 | suppressed |
| Risperidone | Risperidone | 45 | 11 |
| Ezetimibe | Ezetimibe | 44 | suppressed |
| Nifedipine Er | Nifedipine | 44 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 22 |
| Ventolin Hfa | Albuterol Sulfate | 43 | suppressed |
| Valsartan | Valsartan | 42 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | 11 |
| Liothyronine Sodium | Liothyronine Sodium | 40 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 40 | suppressed |
| Sucralfate | Sucralfate | 40 | 15 |
| Brilinta | Ticagrelor | 39 | suppressed |
| Hydrocortisone | Hydrocortisone | 39 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 23 |
| Glipizide | Glipizide | 38 | suppressed |
| Lorazepam | Lorazepam | 38 | 14 |
| Mupirocin | Mupirocin | 38 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 36 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | 11 |
| Trazodone Hcl | Trazodone Hcl | 36 | 13 |
| Ozempic | Semaglutide | 35 | 13 |
| Labetalol Hcl | Labetalol Hcl | 34 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 33 | suppressed |
| Allopurinol | Allopurinol | 33 | 12 |
| Budesonide | Budesonide | 33 | suppressed |
| Nystatin | Nystatin | 33 | 19 |
| Zenpep | Lipase/Protease/Amylase | 33 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Cefdinir | Cefdinir | 32 | 23 |
| Ondansetron Odt | Ondansetron | 32 | 14 |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Gemfibrozil | Gemfibrozil | 31 | suppressed |
| Temazepam | Temazepam | 31 | suppressed |
| Acyclovir | Acyclovir | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Tradjenta | Linagliptin | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 12 |
| Ibuprofen | Ibuprofen | 28 | 15 |
| Acarbose | Acarbose | 27 | suppressed |
| Dutasteride | Dutasteride | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | 11 |
| Cephalexin | Cephalexin | 25 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 25 | 17 |
| Topiramate | Topiramate | 25 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 24 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 24 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 24 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | 15 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 19 | 12 |
| Diazepam | Diazepam | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Permethrin | Permethrin | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Microgestin Fe | Norethindrone-E.Estradiol-Iron | 16 | suppressed |
| Novolin R | Insulin Regular, Human | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Pentoxifylline | Pentoxifylline | 16 | suppressed |
| Rhopressa | Netarsudil Mesylate | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 16 | suppressed |
| Dexamethasone | Dexamethasone | 15 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 11 |
| Naproxen | Naproxen | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Modafinil | Modafinil | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 13 |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Procrit | Epoetin Alfa | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Alogliptin | Alogliptin Benzoate | 12 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Norethindrone | Norethindrone | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 11 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,124.60 · 28 records | Novo Nordisk Inc | Cleerly Ischemia, Cleerly Labs, ELIQUIS, Exablate, Kerendia, LEQVIO, Leqembi, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, REPATHA, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error